According to Future Market Insights, the global Anti-Osteoporosis Therapy And Fracture Healing Market is expected to be valued at US$ 14,051.6 million in 2023. During the 2023 to 2033 forecast period, a CAGR of 4.8% is expected to be registered, with an expected valuation of USS 22,427.6 million by 2033.
The rising prevalence of bone diseases such as osteoporosis has resulted in a greater demand for related drugs. Additionally, the establishment of trauma centers in remote areas can contribute to an increase in the utilization of anti-osteoporosis therapy medications. Unhealthy eating habits and lifestyle changes in the 21st century have led to a significant rise in bone diseases worldwide. A diet deficient in calcium can increase the risk of fractures, early bone loss, and reduced bone density. People who are physically inactive are more prone to develop osteoporosis than those who are physically active.
Experience The Cutting-Edge Of Innovation And Success With Our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-1008
Studies have shown that smoking can also contribute to brittle bones. The consumption of more than one alcoholic drink per day for women or two alcoholic drinks per day for men can further increase the risk of osteoporosis. Consequently, the risk of diseases such as osteoporosis is increasing, which is expected to drive market growth during the forecast period.
The market is anticipated to witness significant growth due to innovations in osteoporosis treatment and the development of new drugs with fewer side effects. A team of innovators at Purdue University has recently developed a new form of drug to treat osteoporosis that may provide a better treatment option for patients with minimal side effects. Similar kind of developments like these are anticipated to create new growth opportunities for the market expansion during the forecast period.
Key Takeaways:
- North America is expected to dominate the market while growing with a CAGR of 4.5% during the forecast period.
- The market in India is projected to witness a CAGR of 4.4% during the forecast period.
- The market in China is expected to grow at a 4.6% CAGR during the forecast period.
- By drug type, bisphosphonate drugs are projected to lead the segment and is estimated to grow with a CAGR of 6%.
- By route of administration, the oral segment is expected to lead the market, growing at a CAGR of 6.2%
“Increasing healthcare expenditure and innovations in treatment drugs and therapies are expected to drive market growth during the forecast period,” comments an FMI Analyst
Competitive Landscape:
The anti-osteoporosis therapy and fracture healing market is extremely competitive and consists of various key industry players. These players are heavily investing in the anti-osteoporosis therapy and fracture healing drugs market.
The key industry players are: Eli Lilly and Company, Pfizer, Inc, Amgen Inc., Merck, and Company Inc., Novartis International AG, F. Hoffmann La Roche Ltd., Teva Pharmaceuticals Industries Ltd., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson.
Some Recent Developments In The Market Are:
- In March 2022, Teva Pharmaceuticals declared the launch of a generic version of Revlimid in the United States.
- Enzene Biosciences Ltd.’s biosimilar drug, Denosumab, received Marketing Authorization (MA) from the Drug Controller General of India (DCGI) in August 2021 for the treatment of osteoporosis in adults.
- In 2021, the United States Food and Drug Administration (FDA) authorized the use of Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk of fracture. The drug is marketed by Amgen.
More Valuable Insights Available:
Future Market Insights offers an unbiased analysis of the global anti-osteoporosis therapy and fracture healing market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the anti-osteoporosis therapy and fracture healing market, the market is segmented on the basis of drug type, route of administration, distribution channel and region.
Unveil New Perspectives Through Our Innovative Methodology! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1008
Key Segments Profiled in the Anti-Osteoporosis Therapy and Fracture Healing Industry Survey
By Drug Type:
- Bisphosphonates
- Calcitonin
- Hormone Replacement Therapy
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- E-Commerce
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
